N/A N=240 Self-learning vs Instructor-led Learning in BLS
Basic Life Support
Primary: Percentage of Correct Compressions — 48; 42; 28; 47 percentage of correct compressions
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=49 Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Participants With Type 2 Diabetes
Type 2 Diabetes Mellitus
Primary: Change From Baseline to Day 28 in Plasma Glucose Area Under the Concentration Time-curve From Time 0 to 4 Hours (AUC0-4hrs) as Measured by Mixed-meal Tolerance Test…
N/A N=329 Diagnostic Accuracy of On-line Quantitative Flow Ratio (QFR). FAVOR II Europe-Japan
Coronary Artery Disease
Primary: Sensitivity: Proportion of Patients With Positive QFR of FFR Positive Patients (True Positives) Compared to Proportion of Patients With Positive Percentual Diameter…
N/A N=9 18F-FLT PET/CT in Measuring Cell Proliferation in Patients With Brain Tumors
Metastatic Malignant Neoplasm in the Brain · Primary Brain Neoplasm · Recurrent Brain Neoplasm
Primary: Percentage Change in Measure of FLT Flux — -4; 3 percent change
N/A N=71 STYLE -- A Trial of Cell Enriched Adipose For Androgenetic Alopecia
Alopecia, Androgenetic
Primary: Safety & Tolerability Assessment of SAE/AE — 5; 9; 12; 2 events
Phase 4 N=219 Quantitative Subharmonic Breast Imaging
Breast Cancer
Primary: Number of Breast Cancer Lesions Characterized as Malignant or Benign With 3D SHI, Harmonic Imaging (HI) or Power Doppler Imaging (PDI) — 69; 24; 126; 58 lesions
N/A N=231 Causes and Circumstances of Horse Related Injuries and Impact on Quality of Life
Injury
Primary: Injury Severity Score (ISS) — 11.3 units on a scale
Phase 2 N=48 Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa
Epidermolysis Bullosa
Primary: Participants With Documented Complete Closure Of The Target Wound Within 1 Month After Initiation Of Treatment — 8; 6; 7; 7 Participants — p==0.3699
Phase 4 N=39 Examination of the Anti-inflammatory and Insulin Sensitizing Properties of Doxycycline in Humans
Type 2 Diabetes · Obesity
Primary: MMP Activity — 56.8; 43.8; 47.2 uM 5-FAM/h-ug protein
N/A N=256 Radiesse® Safety Study For the Treatment of Hands
Volume Loss in the Dorsum of the Hand
Primary: Proportion of Subjects With Device-and/or Injection-related Severe Treatment-emergent Adverse Events (TEAEs) in the Grade 4 Hands Group Versus the Grade 2-3 Hands Group…
N/A N=105 Clinical Study Evaluating the Performance of HEMOBLAST Bellows Compared to FLOSEAL Hemostatic Matrix in Cardiothoracic Operations
Cardiothoracic Surgery
Primary: 3 Minute Hemostasis - Hemostatic Success (Yes/no) at 3 Minutes — 34; 5 Participants
Phase 2 N=87 Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients
Cystic Fibrosis
Primary: Change From Baseline in MRSA Sputum Density. — -0.25; -0.30; -0.63; 0.16 Log10 CFU/mL
N/A N=60 Tesamorelin Effects on Liver Fat and Histology in HIV
Human Immunodeficiency Virus (HIV) · Nonalcoholic Fatty Liver Disease (NAFLD) · Nonalcoholic Steatohepatitis (NASH)
Primary: Change in Liver Fat as Measured by 1-H Magnetic Resonance Spectroscopy — -4.7; 0.0 percent (hepatic fat fraction)
Phase 3 N=574 Bioequivalence Study of Tretinoin Gel 0.05% to Brand Tretinoin Gel
Acne
Primary: Percent Change in Baseline Acne Lesions at Week 12 — -32.34; -37.32; -26.38 Percent reduction
Phase 2 N=59 Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL
Lymphoma, Mantle-Cell
Primary: Freedom From Molecular Residual Disease (MRD) Post-autologous Stem Cell Transplant (ASCT) — 41 Participants